Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.42 |
| ▸ | PTPRF | P10586 | 2/20 | 0.42 |
| ▸ | PTPRA | P18433 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26241850 | 0.93 | PTPN1 (0.41) | IGF2BP2DHODHPTPN1PTPRFPTPRA | |
| SCHEMBL26242454 | 0.93 | DHODH (0.45) | IGF2BP2DHODHPTPN1PTPRFPTPRA | |
| SCHEMBL30173780 | 0.89 | DHODH (0.47) | IGF2BP2DHODHPTPN1PTPRFPTPRA | |
| SCHEMBL23782602 | 0.89 | DHODH (0.47) | IGF2BP2DHODHPTPN1PTPRFPTPRA | |
| SCHEMBL23792006 | 0.86 | TP53 (0.46) | IGF2BP2DHODHPTPN1PTPRFPTPRA | |
| SCHEMBL26241852 | 0.84 | MAPT (0.48) | DHODHTP53MAPT | |
| SCHEMBL26242452 | 0.83 | PTPN1 (0.39) | DHODHPTPN1PTPRFRORCMAPT | |
| SCHEMBL23782583 | 0.82 | DHODH (0.49) | DHODHTP53MAPT | |
| SCHEMBL30173735 | 0.82 | DHODH (0.49) | DHODHTP53MAPT | |
| SCHEMBL23791732 | 0.81 | IGF2BP2 (0.44) | IGF2BP2DHODHPTPN1PTPRFPTPRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2021178488-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | IGF2BP2 255/4885DHODH 3236/4885PTPN1 2774/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | IGF2BP2 255/4885DHODH 3236/4885PTPN1 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.